Clinical Significance of Serum Chemokines in Esophageal Cancer

Background The aim of this study was to detect the expression levels of chemokines (CX3CL1, CXCL-11, CXCL-12, CCL3, CCL4, and CCL20) in the serum of esophageal cancer patients and a normal control group, and to explore the correlations of those expression levels with the pathological type, progression, and metastasis of esophageal cancer. Material/Methods A total of 50 normal people and 50 untreated patients initially diagnosed with esophageal cancer (including 17 cases of non-metastatic esophageal cancer, 33 cases of metastatic esophageal cancer, 36 cases of esophageal squamous cell carcinoma and 14 cases of esophageal adenocarcinoma) were collected. The liquid chip (Luminex) technology was applied to detect the expression levels of the above-mentioned serum chemokines in the two groups. The results were analyzed using Statistical Product and Service Solution 20.0 software. Results The expression levels of CX3CL1, CXCL-12, and CCL20 in esophageal cancer group were evidently higher than those in normal control group (P<0.001, P<0.001 and P=0.003, respectively). There were no statistically significant differences in chemokine expressions between metastatic esophageal cancer group and non-metastatic esophageal cancer group (P>0.05). The expression level of serum CCL4 in esophageal adenocarcinoma group was remarkably higher than that in esophageal squamous cell carcinoma group [18.45 (11.94) versus 13.37 (9.29), Z=−2.039, P=0.031]. In esophageal cancer group and normal control group, the serum CX3CL1 was positively correlated with CCL20 (r=0.649, P<0.001, r=0.758, P<0.001). Conclusions The expressions of serum CX3CL1, CXCL-12, and CCL20 are increased markedly in the patients, which may promote the occurrence, development and metastasis of esophageal cancer.

[1]  W. Jia,et al.  Expression and Association of Tumor Necrosis Factor Receptor Associated Factor 4 (TRAF4) in Esophageal Squamous Cell Carcinoma , 2019, Medical science monitor : international medical journal of experimental and clinical research.

[2]  Xiaoqian Hu,et al.  A suggested framework for conducting esophageal cancer screening in China , 2018, Journal of digestive diseases.

[3]  Diego Romero,et al.  The relationship between chemokines CCL2, CCL3, and CCL4 with the tumor microenvironment and tumor-associated macrophage markers in colorectal cancer , 2018, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[4]  J. Hunter,et al.  Specific Tumor Characteristics Predict Upstaging in Early-Stage Esophageal Cancer , 2018, Annals of Surgical Oncology.

[5]  M. Uguccioni,et al.  Chemokine Heterocomplexes and Cancer: A Novel Chapter to Be Written in Tumor Immunity , 2018, Front. Immunol..

[6]  E. Alici,et al.  The Role of CXC Chemokine Receptors 1–4 on Immune Cells in the Tumor Microenvironment , 2018, Front. Immunol..

[7]  Yi-Xun Liu,et al.  A miR-125b/CSF1-CX3CL1/tumor-associated macrophage recruitment axis controls testicular germ cell tumor growth , 2018, Cell Death & Disease.

[8]  Seong-Hyop Kim,et al.  Association of Chemokines and Chemokine Receptor Expression with Monocytic-Myeloid-Derived Suppressor Cells during Tumor Progression , 2018, Immune network.

[9]  W. Jia,et al.  Overexpression of Coiled-Coil Domain-Containing Protein 34 (CCDC34) and its Correlation with Angiogenesis in Esophageal Squamous Cell Carcinoma , 2018, Medical science monitor : international medical journal of experimental and clinical research.

[10]  R. Samaniego,et al.  CCL20 Expression by Tumor-Associated Macrophages Predicts Progression of Human Primary Cutaneous Melanoma , 2018, Cancer Immunology Research.

[11]  D. Gavrilovic,et al.  Curative intent for unresectable advanced squamous cell esophageal cancer: Overall survival after chemoradiation. , 2017, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[12]  A. Špaks.  Role of CXC group chemokines in lung cancer development and progression. , 2017, Journal of thoracic disease.

[13]  S. Reddy,et al.  A meta-analysis of CXCL12 expression for cancer prognosis , 2017, British Journal of Cancer.

[14]  B. Mroczko,et al.  The Serum Concentrations of Chemokine CXCL12 and Its Specific Receptor CXCR4 in Patients with Esophageal Cancer , 2016, Disease markers.

[15]  P. Ghadjar,et al.  Chemokine/chemokine receptor pair CCL20/CCR6 in human colorectal malignancy: An overview. , 2016, World journal of gastroenterology.

[16]  D. Chudasama,et al.  Diagnostic Value of Circulating CXC Chemokines in Non-small Cell Lung Cancer. , 2015, Anticancer research.

[17]  T. Niki,et al.  19 Effect of nasopharyngeal carcinoma-derived exosomes on human regulatory T cells , 2015 .

[18]  M. Seshadri,et al.  CXCL12/CXCR4 Blockade by Oncolytic Virotherapy Inhibits Ovarian Cancer Growth by Decreasing Immunosuppression and Targeting Cancer-Initiating Cells , 2014, The Journal of Immunology.

[19]  Kun Hu,et al.  Effect of the LPA-mediated CXCL12-CXCR4 axis in the tumor proliferation, migration and invasion of ovarian cancer cell lines , 2014, Oncology letters.

[20]  Rakesh K. Singh,et al.  Targeting CXCR2 Enhances Chemotherapeutic Response, Inhibits Mammary Tumor Growth, Angiogenesis, and Lung Metastasis , 2013, Molecular Cancer Therapeutics.

[21]  J. Lee,et al.  High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor‐infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma , 2012, Journal of surgical oncology.

[22]  A. Peled,et al.  Involvement of CCR6/CCL20/IL-17 Axis in NSCLC Disease Progression , 2011, PloS one.

[23]  P. Tak,et al.  Chemokine and chemokine receptor blockade in arthritis, a prototype of immune-mediated inflammatory diseases. , 2011, The Netherlands journal of medicine.

[24]  M. Miccoli,et al.  High Serum Levels of CXCL11 in Mixed Cryoglobulinemia Are Associated with Increased Circulating Levels of Interferon-γ , 2011, The Journal of Rheumatology.

[25]  M. Burdick,et al.  The SDF-1/CXCL 12/CXCR4 biological axis in non-small cell lung cancer metastases. , 2004, Chest.

[26]  T. Niki,et al.  Effect of nasopharyngeal carcinoma-derived exosomes on human regulatory T cells. , 2015, Journal of the National Cancer Institute.